Open AccessSafety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
Author(s) -
Masaomi Iyo,
Jun Ishigooka,
Masaru Nakamura,
Reiko Sakaguchi,
Keisuke Okamoto,
Yongcai Mao,
Joyce Tsai,
Alison L. Fitzgerald,
Kentaro Takai,
Tetsuya Higuchi
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s320021
Subject(s) - lurasidone , medicine , positive and negative syndrome scale , adverse effect , akathisia , schizophrenia (object oriented programming) , placebo , antipsychotic , psychiatry , psychosis , alternative medicine , pathology
The goal of this study was to evaluate the safety and effectiveness of lurasidone among patients with schizophrenia in a 12-week open-label extension study.